ANCA VASCULITIS DRUG MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2026 - 2033)

ANCA Vasculitis Drug Market Size and Share Analysis: 2026 - 2033

The ANCA vasculitis drug market is estimated to be valued at USD 574.9 Mn in 2026 and expected to reach USD 836.3 Mn by 2033, witnessing a CAGR of 5.5% over the forecast period (2026-2033). The ANCA vasculitis drug market in 2026 is growing due to rising prevalence, hospitals- based distribution, and more biologics are being used.

Key Takeaways

• Based on Type, the Granulomatosis with Polyangiitis (GPA) segment is expected to lead the market with 45% share in 2026, dominates by prevalence and treatment demand in ANCA vasculitis.
• Based on Drug Type, the rituximab segment is expected to hold 37.8% share in 2026, due to proven efficacy and widespread clinical adoption.
• Based on Distribution Channel, the hospital pharmacies segment is projected to account for 52% share in 2026, driven by infusion-based biologics requiring medical supervision.
• Based on Region, North America is set to lead the ANCA vasculitis drug market with 42% share in 2026. While, Asia Pacific is anticipated to be the fastest growing region.

Market Overview

ANCA Vasculitis is a type of autoimmune disease that causes vasculitis, swelling or inflammation of blood vessels. ANCA stands for Anti-Neutrophilic Cytoplasmic Autoantibody. ANCA vasculitis is an autoimmune disease affecting small blood vessels in the body. Neutrophils are a particular subset of white blood cells that are the target of ANCAs, autoantibodies causing the disease. The ANCA vasculitis drug market is driven by rising prevalence of ANCA-associated vasculitis, increasing awareness, advancements in biologics, improved diagnostics, and growing demand for targeted therapies with better safety and efficacy profiles.

Current Events and their Impacts on the ANCA Vasculitis Drug Market

How do incidence, age, and gender patterns shape the global burden of ANCA-associated vasculitis?

Segmental Insights

ANCA Vasculitis Drug Market Insights, By Drug Type - Rituximab leads drug type due to proven efficacy and widespread clinical adoption

In terms of drug type, the rituximab segment is expected to hold 37.8% share in 2026. It is widely regarded as the primary treatment for GPA and MPA, replacing cyclophosphamide in numerous treatment regimens. It is the most important part of treating ANCA vasculitis around the world due to its effectiveness has been approved by regulators, and is given through an infusion.

For instance, in June 2025, the new UK treatment guidelines for ANCA-associated vasculitis declare that Rituximab is better than cyclophosphamide, especially for relapsing cases. Doctors recommend rituximab for both induction and maintenance therapy, which usually lasts two to four years. This shows that Rituximab is still the best drug for ANCA vasculitis, especially for people with GPA and MPA. 

Which ANCA vasculitis type dominates the market in 2026 due to prevalence and treatment demand?

In terms of type, the Granulomatosis with Polyangiitis (GPA) segment is expected to lead the market with 45% share in 2026, because it is increasingly prevalent than other types of ANCA vasculitis, there is a high demand for biologics like rituximab. Clinical guidelines put GPA treatment at the top of the list, which makes it easy for hospital-based infusion centers to adopt and keep making capital.

For instance, in February 2026, The FDA is conducting an investigation into Amgen's drug Tavneos (avacopan), which is approved for GPA and MPA, because of concerns about the safety and integrity of the trials. Amgen defends its benefit-risk profile.

ANCA Vasculitis Drug Market Insights, By Distribution Channel - Hospital Pharmacies dominate distribution, driven by infusion-based biologics requiring medical supervision

In terms of distribution channel, the hospital pharmacies segment is projected to account for 52% share in 2026. Biologics like rituximab need to be given through an IV while a physician supervises, which keeps hospital sales strong. Centralized procurement, specialist oversight, and patient monitoring make this channel even stronger. Retail and online pharmacies are still not as important for oral therapies like glucocorticoids and avacopan.

Regional Insights

North America ANCA Vasculitis Drug Market Analysis & Trends

North America is expected to dominate the ANCA vasculitis drug market with 42% share in 2026, owing to the advanced healthcare system, strong regulatory approvals, and widespread use of biologics. The region has the biggest market share because it has major pharmaceutical companies, ongoing clinical trials, and good reimbursement policies that make it easier for patients to get care. 

In April 2025, the U.S. Patent Office granted approval for AZD1656, Conduit Pharmaceuticals' primary drug candidate aimed at autoimmune disorders such as ANCA vasculitis. This patent bolsters intellectual property safeguards, paving the way for clinical trials and potential collaborations. This achievement places Conduit in a favorable position to advance new therapies for autoimmune diseases, ultimately expanding treatment choices for patients and creating additional business prospects within the United States.

Asia Pacific ANCA Vasculitis Drug Market Analysis & Trends

Asia Pacific is expected to exhibit the fastest growth, since greater resources is being invested in healthcare, diagnostic tools are getting better, and patients are becoming more aware. Countries like China, India, and Japan are using biologics and precision medicine, which is driving growth and making the region the fastest-growing market in the world. 

For instance, in June 2025, Ono Pharmaceutical and Vertex worked together to make povetacicept, a BAFF/APRIL antagonist for

ANCA Vasculitis Drug Market Outlook Country-Wise

The U.S. ANCA Vasculitis Drug Market Trends

The ANCA vasculitis drug market in the US is highly competitive in 2026 because of the country's advanced healthcare system, strong FDA approvals, and widespread use of biologics. The US is a major market due to it has major pharmaceutical companies, ongoing clinical trials, and good reimbursement policies that make it easier for patients to get care. 

For instance, in June 2025, Fate Therapeutics indicated that it had new clinical data for FT819, its ready-made CAR T-cell therapy. Lupus patients had long-lasting drug-free remissions and good safety outcomes. The FDA has let the program grow to include more autoimmune diseases, such as ANCA vasculitis. This shows how FT819 could change the way people in the US treat these diseases. 

China ANCA Vasculitis Drug Market Trends

In 2026, the ANCA vasculitis drug market is exceptionally busy in China because the country's healthcare infrastructure is growing quickly, more money is being put into advanced therapies, and more individuals are growing awareness about autoimmune diseases. China is a key growth engine in Asia-Pacific due to its expanding diagnostic capabilities and the use of biologics. 

For instance, in March 2025, Henlius received approval in China for a Phase 2 trial of HLX79 and HANLIKANG (rituximab) together in patients with active glomerulonephritis. The study encompasses secondary forms, including ANCA-associated vasculitis. HLX79 seeks to improve B-cell depletion, presenting a prospective therapeutic advancement for patients exhibiting insufficient response to rituximab monotherapy. 

Market Report Scope

ANCA Vasculitis Drug Market Driver

Increasing approvals for ANCA vasculitis drugs

Increasingly regulatory bodies around the world are granting approval to ANCA vasculitis drugs. This shows that people are becoming more confident in their safety and effectiveness. These approvals not only give patients more treatment options, but they also encourage drug companies to invest more money into this area of medicine. As more drugs become available, they become easier to obtain, which leads to more patients using them and doctors prescribing them. This trend greatly helps the ANCA vasculitis drug market growth because regulatory support speeds up the process of bringing new drugs to market and makes the market more competitive for new treatments.

Increasing research and development activities

Major pharmaceutical companies are investing more money into research and development to make better treatments for ANCA vasculitis. Researchers are seeking into new methods, such as biologics and targeted treatments, to help patients get better and have fewer side effects. These kinds of research and development projects add to the list of possible drugs, making sure that new ideas keep coming into the market. This increase in activity directly raises the ANCA Vasculitis drugs market demand, as both patients and healthcare providers are interested in better and more personalized ways to treat the disease.

Analyst Opinion (Expert Opinion)

• Large-scale trials show that rituximab achieves about 70% of patients into remission within six months. This is similar to cyclophosphamide, but it has a lower risk of causing infertility and cancer. Nonetheless, relapse rates are elevated, with more than 50% of patients encountering recurrence within five years, and complications related to infection are common due to immunosuppression. Adjunctive therapies, including reduced-dose glucocorticoids, have demonstrated a 30–40% decrease in serious adverse events relative to standard dosing, underscoring the significance of steroid-sparing strategies. Plasma exchange has been used in the past, but controlled trials have shown that it doesn't help kidney health in the long term.
• New drug development is focused on deeper B-cell depletion (like obinutuzumab and CAR-T therapies) and complement inhibition beyond C5aR1. The goal is to lower the risk of relapse and extend the duration of remission. Studies from the early phases show that complement inhibitors like avacopan make kidney function better and lower the need for glucocorticoids. This is shown by statistically significant improvements in renal endpoints compared to placebo. Studies are still going on for BLyS/APRIL inhibitors like telitacicept and povitacicept. Early data suggest that they may work better when used with rituximab. Even with these improvements, long-term risks like secondary immunodeficiency and heart problems are still major problems, underscoring the need for therapies that balance efficacy with safety.

Market Segmentation

• Global ANCA Vasculitis Drug Market, By Type
• • Granulomatosis with Polyangiitis (GPA) 
  • Microscopic Polyangiitis (MPA)  
  • Eosinophilic Granulomatosis with Polyangiitis (EGPA) 
  • Renal-limited Vasculitis
• Global ANCA Vasculitis Drug Market, By Drug Type
  • Glucocorticoids
  • Cyclophosphamide
  • Rituximab
  • Methotrexate
  • Mycophenolate mofetil
  • Azathioprine
  • Mepolizumab
  • Avacopan 
  • Others
• Global ANCA Vasculitis Drug Market, By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies 
  • Online Pharmacies 
• Global ANCA Vasculitis Drug Market, By Region
  • North America
    • U.S.
    • Canada
  • Latin America
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
  • Europe
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
  • Middle East & Africa
    • GCC Countries
    • Israel
    • Rest of Middle East & Africa
• Key Players
  • ChemoCentryx, Inc.
  • Vifor Pharma
  • GlaxoSmithKline plc
  • Amgen
  • Genentech, Inc.
  • Pfizer Inc.
  • Biogen
  • InflaRx GmbH
  • AstraZeneca.

Sources

Primary Research Interviews

• Rheumatologists
• Nephrologists
• Immunologists / Autoimmune Disease Specialists
• Hospital Pharmacists
• Specialty Drug Distributors
• Clinical Research Professionals in Vasculitis Therapies
• Others

Databases

• Bloomberg Terminal
• Thomson Reuters Eikon
• ClinicalTrials.gov
• Others

Magazines

• Pharmaceutical Executive
• Biopharma Dive
• Fierce Pharma
• Drug Discovery & Development
• MedTech Outlook
• Others

Journals

• The New England Journal of Medicine
• The Lancet Rheumatology
• Arthritis & Rheumatology
• Rheumatology (Oxford)
• Journal of Autoimmunity
• Kidney International
• Others

Newspapers

• Financial Times
• The Wall Street Journal
• Reuters
• Bloomberg News
• The Economic Times
• Others

Associations

• Vasculitis Foundation
• American College of Rheumatology (ACR)
• European Alliance of Associations for Rheumatology (EULAR)
• European Renal Association (ERA)
• International Society of Nephrology (ISN)
• Others

Public Domain Sources

• U.S. Food and Drug Administration (FDA)
• European Medicines Agency (EMA)
• National Institutes of Health (NIH)
• National Center for Biotechnology Information (NCBI)
• ClinicalTrials.gov
• World Health Organization (WHO)
• Centers for Disease Control and Prevention (CDC)
• Others

Proprietary Elements

• CMI Data Analytics Tool
• Proprietary CMI Existing Repository of Information for the Last 8 Years